Page 187 - Read Online

Page 16 of 20 Gim et al. Hepatoma Res 2023;9:51 https://dx.doi.org/10.20517/2394-5079.2023.90

Authors’ contributions
Conceptualization: Badri N
Writing-original draft preparation: Gim G
Writing-review and editing: Badri N
Supervision: Badri N
Read and agreed to the published version of the manuscript: Gim G, Badri N

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future
perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastro
Hepat 2016;13:261-80. DOI PubMed
2. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch
Surg 1993;128:871-7; discussion 877-9. DOI PubMed
3. Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun
2021;27:100354. DOI PubMed
4. Lamarca A, Palmer DH, Wasan HS, et al; on behalf of the Advanced Biliary Cancer (ABC) Working Group. ABC-06 | A randomised
phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy
(ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/
gemcitabine (CisGem) chemotherapy. JCO 2019;37:4003. DOI
5. Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol
2013;5:171-6. DOI PubMed PMC
6. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI
7. Oh D, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence 2022:1.
DOI
8. Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas:
potential targets for intervention. Clin Cancer Res 2018;24:4154-61. DOI PubMed PMC
9. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy):
a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796-807. DOI PubMed PMC
10. Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol
2020;73:315-27. DOI PubMed PMC
11. Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation
sequencing. Oncologist 2014;19:235-42. DOI PubMed PMC
12. Li W, Cui Y, Yin F, et al. BRAF mutation in Chinese biliary tract cancer patients. JCO 2020;38:e16678-e16678. DOI
13. Mondaca S, Razavi P, Xu C, et al. Genomic characterization of ERBB -driven biliary cancer and a case of response to ado-
2
trastuzumab emtansine. JCO Precis Oncol 2019;3:PO.19.00223. DOI PubMed PMC